Camp4 Therapeutics Corporation
CAMP
$5.41
$0.030.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.63% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.63% | -- | -- | -- | -- |
| Cost of Revenue | -16.40% | -3.57% | 10.16% | 4.17% | -6.24% |
| Gross Profit | 14.29% | 11.76% | 5.78% | 4.64% | 12.35% |
| SG&A Expenses | 1.64% | 20.50% | 27.77% | 21.59% | 66.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.64% | 3.23% | 14.71% | 8.41% | 8.98% |
| Operating Income | 8.96% | 2.66% | -2.89% | -1.75% | -4.14% |
| Income Before Tax | -203.37% | -11.98% | -0.09% | 0.15% | -2.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -203.37% | -11.98% | -0.09% | 0.15% | -2.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -203.37% | -11.98% | -0.09% | 0.15% | -2.22% |
| EBIT | 8.96% | 2.66% | -2.89% | -1.75% | -4.14% |
| EBITDA | 8.90% | 2.73% | -2.94% | -1.93% | -4.41% |
| EPS Basic | 2.83% | 97.71% | 97.60% | 97.68% | 97.46% |
| Normalized Basic EPS | 2.83% | 97.79% | 97.60% | 97.68% | 97.46% |
| EPS Diluted | 2.83% | 97.71% | 97.60% | 97.68% | 97.46% |
| Normalized Diluted EPS | 2.83% | 97.79% | 97.60% | 97.68% | 97.46% |
| Average Basic Shares Outstanding | 212.23% | 4,793.20% | 4,068.67% | 4,199.74% | 3,921.92% |
| Average Diluted Shares Outstanding | 212.23% | 4,793.20% | 4,068.67% | 4,199.74% | 3,921.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |